Derek Dirocco, PhD
Dr. DiRocco is a principal at RA Capital Management. He works on both public and private investments and serves on the boards of directors for 89Bio, Inc., Achilles Therapeutics Ltd., CANbridge Pharmaceuticals Inc. and iTeos Therapeutics, Inc. Previously, Dr. DiRocco covered solid tumor oncology landscapes. He holds a B.A. in Biology from College of the Holy Cross and a Ph.D. in Pharmacology from the University of Washington.